I am a breastfeeding mother and i want to know if it is safe to use UNII-32828355LL? Is UNII-32828355LL safe for nursing mother and child? Does UNII-32828355LL extracts into breast milk? Does UNII-32828355LL has any long term or short term side effects on infants? Can UNII-32828355LL influence milk supply or can UNII-32828355LL decrease milk supply in lactating mothers?
- DrLact safety Score for UNII-32828355LL is 1 out of 8 which is considered Safe as per our analyses.
- A safety Score of 1 indicates that usage of UNII-32828355LL is mostly safe during lactation for breastfed baby.
- Our study of different scientific research also indicates that UNII-32828355LL does not cause any serious side effects in breastfeeding mothers.
- Most of scientific studies and research papers declaring usage of UNII-32828355LL safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
At latest update, relevant information on excretion into breast milk was not found. Due to a high serum-protein-binding capacity, excretion of UNII-32828355LL into breast milk in significant levels is unlikely. Since it's neutralized by the acid pH of stomach, capsules with enteric coated granules are used. Because of this, it is thought that the small quantity of UNII-32828355LL that may reach the breast milk would be neutralized by infant's stomach. In addition, absorption is greatly decreased by the presence of food. Both Omeprazole and Pantoprazole pertain to the same chemical group with similar pharmacokinetics that are excreted in non-significant amount into the breast milk. No alteration on serum Prolactin level has been shown.
Because no information is available on the use of UNII-32828355LL during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
The Spanish pharmacovigilance system found one case of a 90-year-old man who developed gynecomastia associated with UNII-32828355LL reported during the time period of 1982 to 2006. The reaction occurred after 32 days of therapy and resolved after discontinuation of the drug.[1]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.